98%
921
2 minutes
20
Cell viability assays are useful for assessing the efficacy of antifungal therapeutics and disinfection strategies in vitro. In recent years these assays have been fundamental for the testing of conventional and novel therapies against the nosocomial fungal pathogen Candida auris. Here we provide detailed descriptions of methods for assessing cellular viability of Candida auris in vitro, such as metabolic assays (XTT and resazurin), colony-forming unit counting, live/dead quantitative PCR, and fluorescent staining for microscopic analyses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-0716-2417-3_10 | DOI Listing |
mBio
September 2025
Department of Biology, Laboratory of Molecular Cell Biology, KU Leuven, Leuven, Flanders, Belgium.
Echinocandins, which target the fungal β-1,3-glucan synthase (Fks), are essential for treating invasive fungal infections, yet resistance is increasingly reported. While resistance typically arises through mutations in Fks hotspots, emerging evidence suggests a contributing role of changes in membrane sterol composition due to mutations. Here, we present a clinical case of () in which combined mutations in and , but not alone, appear to confer echinocandin resistance.
View Article and Find Full Text PDFJ Infect Dev Ctries
August 2025
Hospital Infection Control Committee, Adana City Training and Research Hospital, Adana, Türkiye.
Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.
View Article and Find Full Text PDFCureus
August 2025
Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU.
Candidemia, a common hospital-acquired bloodstream infection, is associated with significant mortality, particularly in cases involving (). The Middle East, including Saudi Arabia, has seen an increasing number of invasive infections. This review examines the epidemiology, risk factors, antifungal susceptibility, clinical manifestations, and mortality associated with , based on published literature from Saudi Arabia.
View Article and Find Full Text PDFJ Infect Public Health
August 2025
Infection Control Center, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China; National Clinical Research Center for Geriatric Disorders (XiangYa Hospital), Changsha, Hunan Province 410008, China; Superbugs and Multidrug Resistant Microbes Infection Control Research Ce
Background: On October 25, 2022, the World Health Organization (WHO) released its first Fungal Priority Pathogen List (FPPL), classifying Cryptococcus neoformans (C. neoformans), Candida auris (C. auris), Aspergillus fumigatus (A.
View Article and Find Full Text PDFMycologia
September 2025
Research Institute for Medical and Health Sciences, University of Sharjah, P.O. Box, Sharjah 27272, United Arab Emirates.
The emergence of , a multidrug-resistant fungal pathogen with unique heterogenic characteristics and clades, raised significant concerns globally, particularly in healthcare settings. pathogenicity resides in its adaptability and resilience, with the ability to form robust biofilms and adhere to host tissues and medical devices. Adhesins, particularly Als3, primarily mediate these processes.
View Article and Find Full Text PDF